Evidence map›Paper›PMID 39699655›Full record

ArticleHeart and vessels2025

Comparing moderate-severe and severe mitral regurgitation in transcatheter aortic valve replacement on 1-year survival: insights from a Japanese Nationwide Registry.

Kaoru Matsuura, Hiraku Kumamaru, Shun Kohsaka, Tomoyoshi Kanda, Hideki Kitahara, Kazuo Shimamura, Yoshio Kobayashi, Goro Matsumiya

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kaoru MatsuuraDepartment of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo Ward, Chiba, Chiba, 260-0856, Japan. km4717jp@yahoo.co.jp.ORCID http://orcid.org/0000-0002-7607-4482
Hiraku KumamaruDepartment of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Shun KohsakaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Tomoyoshi KandaDepartment of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo Ward, Chiba, Chiba, 260-0856, Japan.
Hideki KitaharaDepartment of Cardiology, Chiba University Graduate School of Medicine, Chiba, Japan.
Kazuo ShimamuraDepartment of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Yoshio KobayashiDepartment of Cardiology, Chiba University Graduate School of Medicine, Chiba, Japan.
Goro MatsumiyaDepartment of Cardiovascular Surgery, Chiba University Graduate School of Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo Ward, Chiba, Chiba, 260-0856, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to compare 1-year outcomes after transcatheter aortic valve replacement (TAVR) between patients with moderate-severe MR and severe MR preoperatively using the Japan Transcatheter Valve Therapy (J-TVT) registry. Patients undergoing TAVR for aortic stenosis between August 2013 and December 2019 with preoperative mitral regurgitation of moderate-severe (group MR3) or severe (group MR4) were included. Patients with a history of valve surgery and dialysis patients were excluded. A total of 2017 patients were included, and 1-year follow-up data were obtained from the registry (follow-up rate 98.5%). Propensity-score matching between MR3 and MR4 groups was performed. All-cause mortality and the composite outcome of death and/or heart failure events were compared. Crude data showed that 1-year survival was significantly higher in the MR 3 (89.8%) than MR 4 (84.7%) groups, and freedom from 1-year mortality and heart failure events was also higher in the MR 3 (87.1%) than MR 4 (80.5%) groups (p = 0.0001). After propensity-score matching, 452 cases (226 cases each in MR 3 group and MR 4 group) were extracted. Cox regression model showed no statistical difference in the 1-year survival rate between MR 3 group (84.5%) and MR 4 group (85.5%) (p = 0.84), nor in freedom from 1-year death and/or heart failure events between MR 3 group (80.2%) and MR 4 group (81.6%) (p = 0.72). The 1-year survival rate and freedom from death and/or heart failure events were found to be similar between patients undergoing TAVR with MR grade 3 and MR grade 4.

Indexed as

Aortic ValveAortic Valve StenosisMitral ValveMitral Valve InsufficiencyRegistriesTranscatheter Aortic Valve ReplacementAgedAged, 80 and overEast Asian PeopleFemaleFollow-Up StudiesHumansJapanMalePropensity ScoreRetrospective StudiesAortic valve replacement/implantationOutcomesPrognosisTranscatheter

Identifiers

PMID39699655
PMCPMC12085350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.